Biomarker Discovery and CDx
Vivia offers pharmacological profiling and CDx/biomarker discovery services in patient samples to provide key information for drug development. Vivia can also enable fast deployment of Investigator Sponsored Trials with its European KOL network, where PharmaFlow PM would be used as CDx.
  • We partner with drug developers throughout every stage of drug research and development with our proprietary PharmaFlow Technology Platform, from target discovery to biomarker discovery and companion diagnostic in clinical trials.
  • We are working with more than 20 pharmaceutical and biotechnology companies worlwide to enable precision medicine driven therapies.
  • PharmaFlow PM is a precision medicine platform to personalize the treatment of patients suffering Hematological Malignances.
  • PharmaFlow PM generates clinically predictive data: patients predicted sensitive in 1st line show 92% CR at induction and 75% OS at 3-years *
  • PharmaFlow PM CDx can deliver over 90% complete remission (CR) on your drug clinical trial.
CR 92%
OS 75%
* Results from observational clinical trial with Pethema in Spain in 123 AML patients treated with first line Cytarabine and Idarubicin. Publication ready for early issuance.

Vivia enables early identification of drug resistant clones to unleash targeted molecular biomarker discovery programs, uncovering the molecular basis of resistance of your drug. Vivia offers unique, state of the art, native environment immune-oncology and microenvironment assays.

Vivia offers to its partners proprietary Native Environment Assays in patient’s whole bone marrow, assessing the drug activity in the native tumor microenvironment:
  • Assays include state of the art immune-oncology (IO drugs, CAR-T), and microenvironment assays (BCR inhibitors)
  • Key deliveries of PharmaFlow PM for your drug development:
  • Direct impact in ROI over 90% CR in clinical trials as CDx
  • Identification of early molecular biomarkers of efficacy/resistance
  • Better understanding of MOA & interpatient variability of response
  • Best combos to increase market share & overcome resistance in clinical trials
  • Market positioning vs. SOC and competitive drugs